Checkpoint inhibition: protecting against or predisposing for second primary tumors?
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference4 articles.
1. Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer;Heudel;Ann Oncol,2020
2. Assessment of trends in second primary cancers in patients with metastatic melanoma from 2005 to 2016;Deng;JAMA Netw Open,2020
3. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs;Haslam;JAMA Netw Open,2019
4. The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study;Feller;BMC Cancer,2020
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies;Journal of the European Academy of Dermatology and Venereology;2023-06-12
2. Metachronous malignancies after response to checkpoint inhibition;European Journal of Cancer;2022-10
3. Hematologic malignancies following immune checkpoint inhibition for solid tumors;Cancer Immunology, Immunotherapy;2022-06-13
4. Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor ‘Checkpoint inhibition: protecting against or predisposing for second primary tumors?’ by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs;Annals of Oncology;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3